NFKB1 and diabetes mellitus: In patients with underlying pathologies that additionally amplify ROS production, such as rheumatic valvular heart disease, or those undergoing cardiopulmonary bypass or diabetes, L-carnitine and glycine represent promising potential in targeting NF-κB, Nrf2 [178], and the RAGE-NOX-NF-κB signaling pathway [75].